PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Akbay, 2013, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, Cancer Discov., 3, 1355, 10.1158/2159-8290.CD-13-0310

Atkinson V., Ascierto P.A., Long G.V., Brady B., Dutriaux C., Maio M., et al., 2015. Two-year Survival and Safety Update in Patients With Treatment-naïve Advanced Melanoma Receiving Nivolumab or Dacarbazine in CheckMate 066, SMR.

Azuma, 2014, Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer, Ann. Oncol., 25, 1935, 10.1093/annonc/mdu242

Berry, 2015, Innate vs: adaptive: pD-L1-mediated immune resistance by melanoma, Oncoimmunology, 4, e1029704, 10.1080/2162402X.2015.1029704

Callea, 2015, Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma, Cancer Immunol. Res., 3, 1158, 10.1158/2326-6066.CIR-15-0043

Chen, 2015, Regulation of PD-L1: a novel role of pro-survival signalling in cancer, Ann. Oncol.

Choueiri T.K., Fishman M.N. Escudier B., Kim J.J., Kluger H., Stadler H., et al., 2014. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial:ASCO.

Clarke, 2000, The QUORUM statement, Lancet, 355, 756, 10.1016/S0140-6736(05)72172-3

D'Incecco, 2015, PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br. J. Cancer, 112, 95, 10.1038/bjc.2014.555

Daud, 2014, Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475), Eur. J. Cancer, 50, 48, 10.1016/S0959-8049(14)70266-7

Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824

Gettinger, 2015, Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer, J. Clin. Oncol., 33, 2004, 10.1200/JCO.2014.58.3708

Gibney, 2015, Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma, Clin. Cancer Res., 21, 712, 10.1158/1078-0432.CCR-14-2468

Greenland, 1987, Quantitative methods in the review of epidemiologic literature, Epidemiol. Rev., 9, 1, 10.1093/oxfordjournals.epirev.a036298

Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011

Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat. Med., 21, 1539, 10.1002/sim.1186

Hodi F.S., Sznol M., Kluger H.M., McDermott D.F., Carvajal R.D., Lawrence D.P., et al., 2014. Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial:ASCO.

Kohlhapp, 2015, Molecular pathways mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy, Clin. Cancer Res.

Konishi, 2004, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin. Cancer Res., 10, 5094, 10.1158/1078-0432.CCR-04-0428

Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030

Macaskill, 2001, A comparison of methods to detect publication bias in meta-analysis, Stat. Med., 20, 641, 10.1002/sim.698

Madore, 2015, PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials, Pigm. Cell Melanoma Res., 28, 245, 10.1111/pcmr.12340

Massi, 2014, PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics, Ann. Oncol., 25, 2433, 10.1093/annonc/mdu452

Massi, 2015, The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600, Ann. Oncol., 10.1093/annonc/mdv255

McDermott, 2015, Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab, J. Clin. Oncol., 33, 2013, 10.1200/JCO.2014.58.1041

McLaughlin, 2015, Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer, JAMA Oncol., 1

Moher, 2001, The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials, JAMA, 285, 1987, 10.1001/jama.285.15.1987

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239

Paz-Ares L., Horn L., Borghaei H., Spigel D.R., Steins M., Neal E., et al., 2015. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous (non-SQ) cell non-small cell lung cancer (NSCLC):ASCO.

Postow, 2015, Immune checkpoint blockade in cancer therapy, J. Clin. Oncol., 33, 1974, 10.1200/JCO.2014.59.4358

Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N. Engl. J. Med., 372, 2006, 10.1056/NEJMoa1414428

Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol., 10.1016/S1470-2045(15)00083-2

Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082

Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med., 372, 2521, 10.1056/NEJMoa1503093

Rozali, 2012, Programmed death ligand 2 in cancer-induced immune suppression, Clin. Dev. Immunol., 2012, 656340, 10.1155/2012/656340

Sakuishi, 2010, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, J. Exp. Med., 207, 2187, 10.1084/jem.20100643

Shin, 2015, The evolution of checkpoint blockade as a cancer therapy: what's here, what's next, Curr. Opin. Immunol., 33, 23, 10.1016/j.coi.2015.01.006

Spira A.I., Park K., Mazieres J., Vansteenkiste J., Rittmeyer A., Ballinger M., et al., 2015. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing atezolizumab (MPDL3280A) vs docetaxel in 2L/3L NSCLC (POPLAR):ASCO.

Spranger, 2014, Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment, J. Immunother. Cancer, 2

Stuart, 1994

Sznol, 2013, Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response, Clin. Cancer Res., 19

Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003689

Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin. Cancer Res., 20, 5064, 10.1158/1078-0432.CCR-13-3271

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada, J. Natl. Cancer Inst., 92, 205, 10.1093/jnci/92.3.205

Thompson, 2004, Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target, Proc. Natl. Acad. Sci. U. S. A., 101, 17174, 10.1073/pnas.0406351101

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690

Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954

Wainwright, 2014, Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors, Clin. Cancer Res., 20, 5290, 10.1158/1078-0432.CCR-14-0514

Wargo, 2014, Universes collide: combining immunotherapy with targeted therapy for cancer, Cancer Discov., 4, 1377, 10.1158/2159-8290.CD-14-0477

Weber, 2013, Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma, J. Clin. Oncol., 31, 4311, 10.1200/JCO.2013.51.4802

Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med., 369, 122, 10.1056/NEJMoa1302369

Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.-, Cowey C.L., et al., 2015. Efficacy and safety results from a Phase III trial of nivolumab slone or combined with ipilimumab vs. ipilimumab alone in treatment-naïve patients with advanced melanoma (CheckMate 067); Abstract #LBA1:ASCO.

Woo, 2012, Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape, Cancer Res., 72, 917, 10.1158/0008-5472.CAN-11-1620

Yoshii, 2009, Analysis of the reporting of search strategies in Cochrane systematic reviews, J. Med. Libr. Assoc., 97, 21, 10.3163/1536-5050.97.1.004

van Houwelingen, 2002, Advanced methods in meta-analysis: multivariate approach and meta-regression, Stat. Med., 21, 589, 10.1002/sim.1040

Puzanov, 2015, Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL), J. Clin. Oncol., 33, 3012, 10.1200/jco.2015.33.15_suppl.3012